Evercore ISI initiated coverage of vTv Therapeutics with an Outperform rating and $44 price target. Cadisegliatin, a potential first-in-class, once-daily, oral, liver-selective glucokinase activator being developed as an adjunct to insulin in type 1 diabetes, has "looked comparatively well-behaved to date," the analyst tells investors.
